1. Clinical & Scientific Overview
Insulin Aspart (Rapid-Acting & Biphasic Premixed 30/70) (TIP-MED-000059, Reference Code [4.15]) is classified under
Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04) as a Rapid-Acting Recombinant Human Insulin Analogue (B28 Proline substituted by Aspartic Acid).
Within the Indian regulatory and compendial framework, it is governed under Schedule H & Schedule G Prescription Drug ('Caution: It is dangerous to take this preparation except under medical supervision' — Drugs Rules 1945).
Representative Indian Market Examples (Edition 2.7 Ch 04 [4.15], p. 52): Rapid-Acting (Clear): NovoRapid (Novo Nordisk), Ultra-Fast: Fiasp (Novo); Biphasic Premixed (30% Soluble Aspart + 70% Protamine-Crystallised Aspart, Cloudy): NovoMix 30 (Novo Nordisk) — Strengths & Dosage Forms: Prefilled FlexPen (3 mL), Penfill Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100)
Prefilled FlexPen (3 mL), Penfill Cartridges (3 mL), and Vials (10 mL): 100 IU/mL (U-100)
3. Mechanism of Action & Pharmacodynamics
Rapid-Acting Recombinant Human Insulin Analogue (B28 Proline substituted by Aspartic Acid) acting on target receptor/enzyme pathways in Antidiabetic Medicines, Insulins & GLP-1 Agonists (Ch 04): clinical efficacy is mediated via Rapid-Acting Recombinant Human Insulin Analogue (B28 Proline substituted by Aspartic Acid) for Prandial (mealtime) glycaemic control in Type 1 and Type 2 diabetes mellitus (NovoRapid); twice-daily premixed basal-bolus therapy (NovoMix 30); acute diabetic ketoacidosis / hospital hyperglycaemia (NovoRapid Clear only)..
4. Therapeutic Indications & Evidence-Supported Uses
- Prandial (mealtime) glycaemic control in Type 1 and Type 2 diabetes mellitus (NovoRapid)
- twice-daily premixed basal-bolus therapy (NovoMix 30)
- acute diabetic ketoacidosis / hospital hyperglycaemia (NovoRapid Clear only)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: General Adult Reference: Individualised per meal carbohydrate content and pre-meal glucose. Pharmacokinetic Profile: • NovoRapid (Clear): Onset 10–20 min, Peak 1–3 h, Duration 3–5 h. • NovoMix 30 (Cloudy): Onset 10–20 min, Peak 1–4 h, Duration up to 18–24 h.
Administration & Meal Timing: CRITICAL 0–10 MINUTE MEAL RULE: Inject immediately before (within 5–10 minutes of starting) a meal! Unlike Human Regular/Mixtard (which require a 30-minute wait), Insulin Aspart enters the bloodstream within 10 minutes—waiting 30 minutes before eating will cause acute hypoglycaemia before the first bite is swallowed! (In frail elderly with unpredictable appetite, NovoRapid may even be injected immediately after the meal begins). | NovoRapid: Immediately before breakfast, lunch, and dinner (basal-bolus regimen). NovoMix 30: Immediately before breakfast and dinner.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal & Hepatic: Dosing depends on renal and hepatic function; reduce dose as eGFR drops <45 mL/min, though rapid-acting analogues clear faster than regular human insulin, reducing late stacking hypoglycaemia.
Renal & Hepatic: Dosing depends on renal and hepatic function; reduce dose as eGFR drops <45 mL/min, though rapid-acting analogues clear faster than regular human insulin, reducing late stacking hypoglycaemia.
Renal & Hepatic: Dosing depends on renal and hepatic function; reduce dose as eGFR drops <45 mL/min, though rapid-acting analogues clear faster than regular human insulin, reducing late stacking hypoglycaemia.
7. Contraindications, Precautions & High-Risk Warnings
- Contraindicated during hypoglycaemia. NovoMix 30 (cloudy) must NEVER be given IV! Verify carefully whether the patient has been prescribed NovoRapid (Clear, orange label) vs. NovoMix 30 (Cloudy, blue label)—look-alike pen names are a frequent source of dispensing and home-administration errors.
Key Clinical Precautions: Renal & Hepatic: Dosing depends on renal and hepatic function; reduce dose as eGFR drops <45 mL/min, though rapid-acting analogues clear faster than regular human insulin, reducing late stacking hypoglycaemia.
8. Adverse Effects Profile
- Postprandial hypoglycaemia (if meal is delayed or low in carbohydrates), weight gain, injection-site lipohypertrophy.
- Severe neuroglycopenic hypoglycaemia, hypokalaemia.
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Beta-blockers mask tachycardia/tremor of hypoglycaemia; alcohol, ACE inhibitors, sulfonylureas (normally discontinued when starting basal-bolus or premixed insulin), and fluoroquinolones increase hypoglycaemia risk
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Contrast clearly with old human insulin: 'With NovoRapid or NovoMix, your plate of food must already be in front of you when you inject—eat within 5 to 10 minutes!' If dispensing NovoMix 30, teach the patient to roll and invert the cloudy pen 10 times until milky white before every dose.
- Meal & Clock Timing Instruction: CRITICAL 0–10 MINUTE MEAL RULE: Inject immediately before (within 5–10 minutes of starting) a meal! Unlike Human Regular/Mixtard (which require a 30-minute wait), Insulin Aspart enters the bloodstream within 10 minutes—waiting 30 minutes before eating will cause acute hypoglycaemia before the first bite is swallowed! (In frail elderly with unpredictable appetite, NovoRapid may even be injected immediately after the meal begins). (NovoRapid: Immediately before breakfast, lunch, and dinner (basal-bolus regimen). NovoMix 30: Immediately before breakfast and dinner.)
- Missed Dose Protocol: If forgotten before the meal, NovoRapid may be injected during or immediately after completing the meal. For NovoMix 30, if remembered well after the meal, check blood glucose and consult the physician—never double the next dose.
- Geriatric Dispensing Pearl: In elderly dementia or stroke patients whose food intake varies from meal to meal, rapid-acting Insulin Aspart (NovoRapid) offers a major safety advantage because it can be administered right after observing how much food the patient actually ate.
Storage, Stability & Dispensing Safeguards: COLD CHAIN MANDATORY (2°C–8°C): Store in a pharmaceutical refrigerator between 2°C and 8°C; DO NOT FREEZE. Protect from light and heat during dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 04 [4.15] (p. 52)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [4.13]-C16 Biphasic Isophane Insulin 30/70 — Recombinant Human Peptide Hormone; Short-Acting (Regular), Interm
- [4.18]-C17 Alogliptin — Dipeptidyl Peptidase-4 (DPP-4) Inhibitors (Schedule H)
- [4.22]-C18 Dulaglutide — Subcutaneous GLP-1 Receptor Agonists (Schedule H | 2°C–8°C Cold C
- [4.24]-C19 Intravenous Dextrose (25% / 50%) — Hyperglycaemic Glycogenolytic Hormone & Emergency Carbohydrate Re
